Drugs / Meditoxin
Meditoxin
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03647982 | Mar → Oct 2018 | anhidrosis, isolated hyperchlorhidrosis | Medy-Tox | Completed | No outcome recorded |
| Phase 1 | NCT03371342 | Dec 2017 → May 2018 | overactive bladder | Medy-Tox | Completed | No outcome recorded |
| Phase 1 | NCT03317717 | Oct 2017 → Jan 2018 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT03760198 | Aug 2018 → Jul 2019 | isolated hyperchlorhidrosis | Medy-Tox | Completed | No outcome recorded |
| Phase 3 | NCT03452345 | Apr 2018 → Jan 2019 | masticatory muscles, hypertrophy of | Medy-Tox | Completed | No outcome recorded |
| Phase 3 | NCT03232320 | Jul 2017 → Oct 2018 | dystonic disorder | Medy-Tox | Completed | No outcome recorded |
| Phase 3 | NCT01313767 | Mar 2011 → Jan 2012 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT03289169 | Dec 2016 → May 2019 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 4 | NCT02757404 | May → Aug 2016 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 4 | NCT03908580 | Sep 2013 → Oct 2014 | — | Medy-Tox | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT00682760 Comparator | Oct 2005 → Feb 2006 | benign essential blepharospasm | Pacific Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01860196 Comparator | Jun 2013 → Mar 2017 | cerebral palsy | Seoul National University Hospital | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDITOXIN | “PURPOSE: To compare the efficacies and safeties of Meditoxin (Medy-Tox, Korea) and Botox in the treatment of essential blepharospasm.” PMID 19794937 ↗ Sep 200913“injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses” NCT03317717 ↗ “MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity” NCT01313767 ↗ “injection of MEDITOXIN into the intradermal of each contralateral upper back in equal doses” NCT03647982 ↗ |
| Known as | Botulinum toxin type A | “Meditoxin (Botulinum toxin type A)” NCT03452345 ↗ |
| Known as | Medy-Tox | “PURPOSE: To compare the efficacies and safeties of Meditoxin (Medy-Tox, Korea) and Botox in the treatment of essential blepharospasm.” PMID 19794937 ↗ Sep 2009 |
| Modality | Protein / enzyme biologic | “Meditoxin (Botulinum toxin type A)” NCT03232320 ↗ |
| Route | Other | “Meditoxin® will be injected to upper limb spasticity by using the ultrasonography guidance.” NCT02757404 ↗ |